| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02P20-55 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-073 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07B61-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-06 |
| filingDate |
2005-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2008-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2008531680-A |
| titleOfInvention |
Intermediates and methods for the preparation of 21-deoxy-21,21-difluoro-D-ribofuranosyl nucleosides enriched in beta anomers |
| abstract |
The present invention relates to 2 1 -deoxy-2 1 , 2 1 -D-ribofuranosyl difluoronucleoside [formula (II)] enriched in β-anomer, and physiologically acceptable salts thereof, in particular gemcitabine hydrochloride Highly selective, simple by utilizing the novel trichloroacetimidate of formula (I) to prepare the β-enriched anomer of the salt [formula (IIb)] with a purity higher than 99%, An economical glycosylation method is provided. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7111625-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018124172-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10919829-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2018124172-A1 |
| priorityDate |
2005-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |